| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.697 | 0.007 | 0.889 | 5 Hydroxytryptamine release stimulant | 0.885 0.002 DBMET00621 0.889 0.002 DBMET00634 | DBMET00634 | |
| 0.65 | 0.005 | 0.785 | Psychostimulant | 0.682 0.004 DBMET00621 0.785 0.004 DBMET00634 | DBMET00634 | |
| 0.576 | 0.009 | 0.576 | Cardiotonic | 0.358 0.037 DBMET00634 | ||
| 0.479 | 0.005 | 0.754 | 5 Hydroxytryptamine uptake stimulant | 0.754 0.001 DBMET00621 0.563 0.003 DBMET00634 | DBMET00621 | |
| 0.485 | 0.018 | 0.485 | Vasodilator, coronary | 0.387 0.04 DBMET00621 0.451 0.023 DBMET00634 | ||
| 0.48 | 0.026 | 0.56 | Spasmolytic | 0.408 0.038 DBMET00621 0.56 0.017 DBMET00634 | DBMET00634 | |
| 0.36 | 0.005 | 0.36 | Neurotrophic factor | 0.143 0.066 DBMET00621 0.178 0.039 DBMET00634 | ||
| 0.353 | 0.015 | 0.653 | Tyrosine 3 hydroxylase inhibitor | 0.653 0.003 DBMET00621 0.442 0.005 DBMET00634 | DBMET00621 | |
| 0.35 | 0.034 | 0.393 | Insulysin inhibitor | 0.393 0.023 DBMET00621 0.364 0.03 DBMET00634 | DBMET00621 | |
| 0.391 | 0.084 | 0.614 | 5 Hydroxytryptamine release inhibitor | 0.614 0.009 DBMET00621 0.504 0.031 DBMET00634 | DBMET00621 | |
| 0.356 | 0.062 | 0.389 | Cholesterol antagonist | 0.35 0.064 DBMET00621 0.389 0.052 DBMET00634 | DBMET00634 | |
| 0.344 | 0.056 | 0.522 | Aldehyde oxidase inhibitor | 0.522 0.03 DBMET00621 0.4 0.047 DBMET00634 | DBMET00621 | |
| 0.297 | 0.01 | 0.297 | Calcium channel blocker | 0.185 0.036 DBMET00634 | ||
| 0.351 | 0.073 | 0.372 | Vasodilator, peripheral | 0.342 0.077 DBMET00621 0.372 0.065 DBMET00634 | DBMET00634 | |
| 0.314 | 0.042 | 0.415 | Interleukin agonist | 0.415 0.017 DBMET00621 0.345 0.03 DBMET00634 | DBMET00621 | |
| 0.298 | 0.031 | 0.298 | 5 Hydroxytryptamine 1E antagonist | 0.261 0.063 DBMET00621 0.278 0.046 DBMET00634 | ||
| 0.286 | 0.022 | 0.286 | MAO inhibitor | 0.19 0.044 DBMET00621 0.199 0.041 DBMET00634 | ||
| 0.279 | 0.018 | 0.279 | Acetylcholine M1 receptor antagonist | 0.205 0.04 DBMET00621 0.206 0.04 DBMET00634 | ||
| 0.275 | 0.015 | 0.275 | Anesthetic local | 0.204 0.031 DBMET00621 0.251 0.02 DBMET00634 | ||
| 0.262 | 0.012 | 0.3 | 5 Hydroxytryptamine 3E antagonist | 0.282 0.007 DBMET00621 0.3 0.005 DBMET00634 | DBMET00634 | |
| 0.333 | 0.095 | 0.369 | Calpain 2 inhibitor | 0.369 0.077 DBMET00621 0.359 0.082 DBMET00634 | DBMET00621 | |
| 0.248 | 0.015 | 0.248 | Acetylcholine muscarinic antagonist | 0.14 0.05 DBMET00621 0.156 0.04 DBMET00634 | ||
| 0.236 | 0.01 | 0.236 | Calcium channel N-type blocker | 0.127 0.055 DBMET00621 0.182 0.022 DBMET00634 | ||
| 0.246 | 0.022 | 0.246 | Cholinergic antagonist | 0.13 0.065 DBMET00621 0.183 0.037 DBMET00634 | ||
| 0.245 | 0.023 | 0.245 | Nav1.2 sodium channel blocker | 0.211 0.031 DBMET00621 0.228 0.026 DBMET00634 | ||
| 0.281 | 0.06 | 0.281 | Ca(v)3.3 blocker | 0.209 0.172 DBMET00621 0.232 0.13 DBMET00634 | ||
| 0.242 | 0.022 | 0.242 | Acetylcholine antagonist | 0.127 0.064 DBMET00621 0.176 0.038 DBMET00634 | ||
| 0.335 | 0.117 | 0.335 | Analgesic | 0.241 0.19 DBMET00621 0.303 0.139 DBMET00634 | ||
| 0.229 | 0.012 | 0.229 | Nav1.6 sodium channel blocker | 0.166 0.038 DBMET00621 0.191 0.023 DBMET00634 | ||
| 0.262 | 0.054 | 0.302 | Calpain inhibitor | 0.302 0.029 DBMET00621 0.28 0.041 DBMET00634 | DBMET00621 | |
| 0.221 | 0.016 | 0.221 | MAP kinase kinase 5 inhibitor | |||
| 0.267 | 0.061 | 0.358 | Gastrin inhibitor | 0.31 0.027 DBMET00621 0.358 0.009 DBMET00634 | DBMET00634 | |
| 0.216 | 0.013 | 0.216 | Falcipain 3 inhibitor | 0.211 0.015 DBMET00621 0.216 0.014 DBMET00634 | ||
| 0.22 | 0.019 | 0.22 | Butyrylcholinesterase inhibitor | |||
| 0.253 | 0.053 | 0.283 | Neuropeptide Y2 antagonist | 0.283 0.028 DBMET00621 0.247 0.059 DBMET00634 | DBMET00621 | |
| 0.206 | 0.013 | 0.206 | Calcium antagonist | 0.119 0.036 DBMET00621 0.178 0.016 DBMET00634 | ||
| 0.2 | 0.008 | 0.221 | CYP2A6 inhibitor | 0.221 0.005 DBMET00621 0.131 0.022 DBMET00634 | DBMET00621 | |
| 0.214 | 0.026 | 0.236 | MAO A inhibitor | 0.191 0.031 DBMET00621 0.236 0.023 DBMET00634 | DBMET00634 | |
| 0.344 | 0.157 | 0.473 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.424 0.081 DBMET00621 0.473 0.047 DBMET00634 | DBMET00634 | |
| 0.2 | 0.017 | 0.2 | Calcium channel (voltage-sensitive) blocker | 0.155 0.031 DBMET00634 | ||
| 0.238 | 0.055 | 0.354 | Anesthetic general | 0.354 0.023 DBMET00621 0.298 0.034 DBMET00634 | DBMET00621 | |
| 0.211 | 0.031 | 0.375 | Alpha-N-acetylglucosaminidase inhibitor | 0.375 0.01 DBMET00621 0.352 0.012 DBMET00634 | DBMET00621 | |
| 0.217 | 0.038 | 0.217 | Diuretic | 0.17 0.061 DBMET00621 0.127 0.097 DBMET00634 | ||
| 0.2 | 0.025 | 0.2 | MAO B inhibitor | 0.093 0.064 DBMET00621 | ||
| 0.177 | 0.005 | 0.181 | Sigma 1 receptor antagonist | 0.026 0.019 DBMET00621 0.181 0.005 DBMET00634 | DBMET00634 | |
| 0.195 | 0.024 | 0.297 | Cathepsin H inhibitor | 0.297 0.01 DBMET00621 0.22 0.018 DBMET00634 | DBMET00621 | |
| 0.29 | 0.123 | 0.513 | Antiobesity | 0.387 0.071 DBMET00621 0.513 0.034 DBMET00634 | DBMET00634 | |
| 0.199 | 0.033 | 0.199 | Acetylcholinesterase inhibitor | |||
| 0.272 | 0.107 | 0.272 | Apoptosis antagonist | 0.224 0.153 DBMET00621 | ||
| 0.173 | 0.009 | 0.173 | Acetylcholine M3 receptor antagonist | 0.073 0.03 DBMET00634 | ||
| 0.182 | 0.02 | 0.182 | Ca(v)2.2 blocker | 0.147 0.03 DBMET00634 | ||
| 0.235 | 0.079 | 0.278 | Vasodilator | 0.278 0.056 DBMET00634 | DBMET00634 | |
| 0.238 | 0.083 | 0.561 | Superoxide dismutase inhibitor | 0.561 0.009 DBMET00621 0.28 0.058 DBMET00634 | DBMET00621 | |
| 0.164 | 0.009 | 0.164 | Acetylcholine M2 receptor antagonist | 0.054 0.051 DBMET00634 | ||
| 0.167 | 0.016 | 0.208 | Prolactin inhibitor | 0.208 0.008 DBMET00621 0.172 0.015 DBMET00634 | DBMET00621 | |
| 0.176 | 0.028 | 0.302 | Aminopeptidase B inhibitor | 0.302 0.008 DBMET00621 0.217 0.018 DBMET00634 | DBMET00621 | |
| 0.211 | 0.063 | 0.253 | Insulin sensitizer | 0.253 0.033 DBMET00621 0.24 0.04 DBMET00634 | DBMET00621 | |
| 0.19 | 0.043 | 0.247 | Thiol protease inhibitor | 0.247 0.027 DBMET00621 0.211 0.036 DBMET00634 | DBMET00621 | |
| 0.209 | 0.065 | 0.209 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.192 0.079 DBMET00621 0.164 0.118 DBMET00634 | ||
| 0.149 | 0.011 | 0.159 | Sigma receptor antagonist | 0.047 0.036 DBMET00621 0.159 0.01 DBMET00634 | DBMET00634 | |
| 0.151 | 0.014 | 0.206 | Adrenaline agonist | 0.148 0.015 DBMET00621 0.206 0.006 DBMET00634 | DBMET00634 | |
| 0.17 | 0.037 | 0.192 | Nav1.3 sodium channel blocker | 0.126 0.067 DBMET00621 0.192 0.027 DBMET00634 | DBMET00634 | |
| 0.148 | 0.015 | 0.148 | Analgesic, opioid | 0.144 0.016 DBMET00621 0.111 0.026 DBMET00634 | ||
| 0.155 | 0.022 | 0.172 | Sphingomyelinase inhibitor | 0.145 0.027 DBMET00621 0.172 0.017 DBMET00634 | DBMET00634 | |
| 0.147 | 0.015 | 0.156 | Histamine N-methyltransferase inhibitor | 0.156 0.012 DBMET00621 0.133 0.021 DBMET00634 | DBMET00621 | |
| 0.184 | 0.054 | 0.184 | Cholinergic | |||
| 0.159 | 0.03 | 0.173 | Vanilloid 1 agonist | 0.173 0.022 DBMET00621 0.164 0.027 DBMET00634 | DBMET00621 | |
| 0.166 | 0.04 | 0.21 | Adenylate cyclase stimulant | 0.21 0.01 DBMET00621 0.198 0.014 DBMET00634 | DBMET00621 | |
| 0.159 | 0.034 | 0.307 | Ferrochelatase inhibitor | 0.307 0.007 DBMET00621 0.178 0.028 DBMET00634 | DBMET00621 | |
| 0.145 | 0.027 | 0.194 | Opioid antagonist | 0.194 0.015 DBMET00621 0.15 0.026 DBMET00634 | DBMET00621 | |
| 0.26 | 0.145 | 0.419 | GABA C receptor rho-3 antagonist | 0.419 0.053 DBMET00621 0.387 0.067 DBMET00634 | DBMET00621 | |
| 0.141 | 0.027 | 0.229 | Nitric-oxide synthase inhibitor | 0.229 0.006 DBMET00621 0.204 0.009 DBMET00634 | DBMET00621 | |
| 0.127 | 0.013 | 0.127 | Dopamine uptake inhibitor | 0.088 0.022 DBMET00621 0.114 0.015 DBMET00634 | ||
| 0.141 | 0.031 | 0.157 | Transcription factor STAT6 inhibitor | 0.157 0.019 DBMET00621 0.144 0.028 DBMET00634 | DBMET00621 | |
| 0.301 | 0.192 | 0.537 | Caspase 9 stimulant | 0.413 0.104 DBMET00621 0.537 0.048 DBMET00634 | DBMET00634 | |
| 0.126 | 0.018 | 0.259 | Aminopeptidase I inhibitor | 0.259 0.004 DBMET00621 0.164 0.01 DBMET00634 | DBMET00621 | |
| 0.133 | 0.026 | 0.133 | Acetylcholine nicotinic antagonist | 0.085 0.05 DBMET00621 0.127 0.028 DBMET00634 | ||
| 0.143 | 0.038 | 0.143 | Chelator | |||
| 0.125 | 0.021 | 0.18 | Somatostatin 1 agonist | 0.18 0.009 DBMET00621 0.126 0.021 DBMET00634 | DBMET00621 | |
| 0.104 | 0.004 | 0.104 | Diamine oxidase inhibitor | 0.081 0.005 DBMET00621 0.063 0.008 DBMET00634 | ||
| 0.149 | 0.049 | 0.166 | Heat shock protein 70 antagonist | 0.166 0.021 DBMET00621 0.148 0.05 DBMET00634 | DBMET00621 | |
| 0.147 | 0.048 | 0.186 | Proteasome inhibitor | 0.186 0.03 DBMET00621 0.17 0.036 DBMET00634 | DBMET00621 | |
| 0.116 | 0.019 | 0.116 | Acetylcholine M4 receptor antagonist | |||
| 0.111 | 0.015 | 0.116 | Estrogen-related receptor beta agonist | 0.104 0.02 DBMET00621 0.116 0.012 DBMET00634 | DBMET00634 | |
| 0.154 | 0.059 | 0.176 | Neuropeptide Y1 antagonist | 0.176 0.033 DBMET00621 0.154 0.058 DBMET00634 | DBMET00621 | |
| 0.116 | 0.023 | 0.169 | Alpha adrenoreceptor agonist | 0.1 0.028 DBMET00621 0.169 0.013 DBMET00634 | DBMET00634 | |
| 0.11 | 0.02 | 0.11 | Calcium channel L-type blocker | 0.093 0.029 DBMET00634 | ||
| 0.185 | 0.095 | 0.185 | Anticonvulsant | 0.158 0.12 DBMET00621 0.167 0.11 DBMET00634 | ||
| 0.162 | 0.075 | 0.26 | Neurotensin receptor agonist | 0.26 0.019 DBMET00621 0.257 0.02 DBMET00634 | DBMET00621 | |
| 0.208 | 0.124 | 0.271 | Transcription factor STAT3 inhibitor | 0.271 0.069 DBMET00621 0.256 0.079 DBMET00634 | DBMET00621 | |
| 0.085 | 0.003 | 0.085 | Protease (Human cytomegalovirus) inhibitor | 0.029 0.008 DBMET00621 0.049 0.004 DBMET00634 | ||
| 0.134 | 0.053 | 0.144 | Papain-like protease (SARS coronavirus) inhibitor | 0.12 0.082 DBMET00621 0.144 0.04 DBMET00634 | DBMET00634 | |
| 0.1 | 0.019 | 0.137 | Adrenaline uptake inhibitor | 0.137 0.011 DBMET00621 0.132 0.012 DBMET00634 | DBMET00621 | |
| 0.097 | 0.016 | 0.28 | 5 Hydroxytryptamine 2A agonist | 0.28 0.003 DBMET00621 0.112 0.011 DBMET00634 | DBMET00621 | |
| 0.085 | 0.005 | 0.12 | Immunoglobulin Fc receptor antagonist | 0.106 0.004 DBMET00621 0.12 0.003 DBMET00634 | DBMET00634 | |
| 0.121 | 0.043 | 0.189 | Adenylate kinase inhibitor | 0.189 0.017 DBMET00621 0.108 0.055 DBMET00634 | DBMET00621 | |
| 0.158 | 0.081 | 0.431 | Growth hormone agonist | 0.431 0.012 DBMET00621 0.264 0.04 DBMET00634 | DBMET00621 | |
| 0.129 | 0.053 | 0.179 | 5 Hydroxytryptamine 2B antagonist | 0.179 0.031 DBMET00621 0.16 0.037 DBMET00634 | DBMET00621 | |
| 0.122 | 0.046 | 0.158 | Protease inhibitor | 0.158 0.026 DBMET00621 0.143 0.033 DBMET00634 | DBMET00621 | |
| 0.1 | 0.025 | 0.385 | Phenylalanine 4-hydroxylase inhibitor | 0.385 0.003 DBMET00621 0.199 0.007 DBMET00634 | DBMET00621 | |
| 0.205 | 0.131 | 0.288 | Transcription factor STAT inhibitor | 0.288 0.063 DBMET00621 0.255 0.083 DBMET00634 | DBMET00621 | |
| 0.141 | 0.068 | 0.158 | Ca2+-transporting ATPase inhibitor | 0.158 0.026 DBMET00621 0.147 0.05 DBMET00634 | DBMET00621 | |
| 0.122 | 0.05 | 0.199 | GABA C receptor antagonist | 0.199 0.013 DBMET00621 0.169 0.021 DBMET00634 | DBMET00621 | |
| 0.102 | 0.031 | 0.168 | Opioid mu receptor antagonist | 0.168 0.014 DBMET00621 0.12 0.025 DBMET00634 | DBMET00621 | |
| 0.12 | 0.049 | 0.315 | GABA C receptor agonist | 0.315 0.008 DBMET00621 0.148 0.034 DBMET00634 | DBMET00621 | |
| 0.195 | 0.124 | 0.337 | Immunostimulant | 0.337 0.068 DBMET00621 0.22 0.109 DBMET00634 | DBMET00621 | |
| 0.103 | 0.032 | 0.103 | Opioid kappa receptor antagonist | 0.098 0.036 DBMET00621 0.087 0.049 DBMET00634 | ||
| 0.158 | 0.088 | 0.158 | Catenin beta inhibitor | 0.146 0.116 DBMET00621 0.139 0.135 DBMET00634 | ||
| 0.09 | 0.02 | 0.142 | Protease 3C (Human rhinovirus) inhibitor | 0.142 0.007 DBMET00621 0.118 0.01 DBMET00634 | DBMET00621 | |
| 0.079 | 0.01 | 0.079 | Squalene epoxidase inhibitor | |||
| 0.117 | 0.048 | 0.23 | DOPA decarboxylase inhibitor | 0.23 0.004 DBMET00621 0.138 0.029 DBMET00634 | DBMET00621 | |
| 0.082 | 0.013 | 0.082 | Calcium channel P-type blocker | 0.064 0.042 DBMET00621 | ||
| 0.166 | 0.097 | 0.166 | Amyloid beta aggregation inhibitor | |||
| 0.134 | 0.067 | 0.178 | Sphingosine 1-phosphate receptor 2 antagonist | 0.178 0.016 DBMET00621 0.142 0.053 DBMET00634 | DBMET00621 | |
| 0.118 | 0.052 | 0.129 | Acetylcholine release stimulant | 0.129 0.035 DBMET00621 0.129 0.035 DBMET00634 | DBMET00634 | |
| 0.079 | 0.013 | 0.107 | Nicotinic alpha3beta2 receptor antagonist | 0.078 0.013 DBMET00621 0.107 0.006 DBMET00634 | DBMET00634 | |
| 0.074 | 0.01 | 0.074 | Leukotriene A4 hydrolase inhibitor | 0.054 0.018 DBMET00621 | ||
| 0.094 | 0.03 | 0.094 | CC chemokine 5 receptor agonist | 0.093 0.032 DBMET00621 0.092 0.033 DBMET00634 | ||
| 0.121 | 0.057 | 0.124 | Alpha 2b adrenoreceptor antagonist | 0.119 0.059 DBMET00621 0.124 0.055 DBMET00634 | DBMET00634 | |
| 0.126 | 0.063 | 0.177 | Adenylate cyclase inhibitor | 0.173 0.033 DBMET00621 0.177 0.031 DBMET00634 | DBMET00634 | |
| 0.114 | 0.051 | 0.175 | Carbonic anhydrase XV inhibitor | 0.175 0.023 DBMET00621 0.116 0.05 DBMET00634 | DBMET00621 | |
| 0.083 | 0.021 | 0.128 | Beta 3 adrenoreceptor antagonist | 0.08 0.023 DBMET00621 0.128 0.008 DBMET00634 | DBMET00634 | |
| 0.083 | 0.022 | 0.093 | Human rhinovirus A protease inhibitor | 0.093 0.019 DBMET00621 0.069 0.029 DBMET00634 | DBMET00621 | |
| 0.193 | 0.133 | 0.271 | DNA synthesis inhibitor | 0.271 0.055 DBMET00621 0.212 0.105 DBMET00634 | DBMET00621 | |
| 0.082 | 0.022 | 0.082 | 5 Hydroxytryptamine 5A antagonist | 0.075 0.027 DBMET00634 | ||
| 0.098 | 0.039 | 0.183 | Inducible nitric-oxide synthase inhibitor | 0.174 0.012 DBMET00621 0.183 0.01 DBMET00634 | DBMET00634 | |
| 0.088 | 0.029 | 0.105 | Vanilloid 4 agonist | 0.092 0.024 DBMET00621 0.105 0.013 DBMET00634 | DBMET00634 | |
| 0.181 | 0.125 | 0.28 | Nitric-oxide synthase stimulant | 0.28 0.017 DBMET00621 0.236 0.043 DBMET00634 | DBMET00621 | |
| 0.105 | 0.05 | 0.128 | Interleukin 1 beta converting enzyme inhibitor | 0.115 0.039 DBMET00621 0.128 0.029 DBMET00634 | DBMET00634 | |
| 0.07 | 0.015 | 0.071 | Prolyl endopeptidase inhibitor | 0.071 0.015 DBMET00621 0.06 0.024 DBMET00634 | DBMET00621 | |
| 0.153 | 0.1 | 0.242 | Phospholipase C inhibitor | 0.242 0.027 DBMET00621 0.164 0.081 DBMET00634 | DBMET00621 | |
| 0.066 | 0.013 | 0.066 | Gonadotropin-releasing hormone receptor antagonist | |||
| 0.063 | 0.011 | 0.063 | Benzodiazepine antagonist | |||
| 0.063 | 0.011 | 0.063 | Substance P antagonist | |||
| 0.115 | 0.063 | 0.166 | Photosensitizer | 0.166 0.023 DBMET00621 0.136 0.041 DBMET00634 | DBMET00621 | |
| 0.111 | 0.06 | 0.111 | Electron transport complex I inhibitor | |||
| 0.104 | 0.053 | 0.138 | Glutamate (mGluR7) agonist | 0.138 0.017 DBMET00621 0.126 0.024 DBMET00634 | DBMET00621 | |
| 0.069 | 0.019 | 0.203 | 5 Hydroxytryptamine 2 agonist | 0.203 0.004 DBMET00621 0.138 0.005 DBMET00634 | DBMET00621 | |
| 0.105 | 0.056 | 0.123 | Folate antagonist | 0.108 0.052 DBMET00621 0.123 0.037 DBMET00634 | DBMET00634 | |
| 0.06 | 0.012 | 0.06 | Factor XIIIa inhibitor | 0.04 0.023 DBMET00621 0.034 0.03 DBMET00634 | ||
| 0.144 | 0.095 | 0.169 | Arachidonic acid antagonist | 0.169 0.067 DBMET00621 0.151 0.087 DBMET00634 | DBMET00621 | |
| 0.06 | 0.012 | 0.06 | Plasmepsin II inhibitor | 0.056 0.014 DBMET00621 0.048 0.019 DBMET00634 | ||
| 0.069 | 0.021 | 0.108 | Glycine transporter 2 inhibitor | 0.108 0.012 DBMET00621 0.057 0.026 DBMET00634 | DBMET00621 | |
| 0.087 | 0.039 | 0.176 | Cathepsin G inhibitor | 0.176 0.018 DBMET00621 0.101 0.033 DBMET00634 | DBMET00621 | |
| 0.06 | 0.013 | 0.06 | Neurokinin 2 agonist | 0.058 0.014 DBMET00621 0.04 0.03 DBMET00634 | ||
| 0.072 | 0.025 | 0.072 | 5 Hydroxytryptamine 5 antagonist | 0.067 0.028 DBMET00634 | ||
| 0.069 | 0.022 | 0.086 | Beta 2 adrenoreceptor agonist | 0.079 0.009 DBMET00621 0.086 0.006 DBMET00634 | DBMET00634 | |
| 0.149 | 0.103 | 0.175 | ATPase inhibitor | 0.157 0.089 DBMET00621 0.175 0.065 DBMET00634 | DBMET00634 | |
| 0.05 | 0.005 | 0.074 | Tryptophan 5 hydroxylase inhibitor | 0.074 0.003 DBMET00621 0.047 0.007 DBMET00634 | DBMET00621 | |
| 0.061 | 0.016 | 0.064 | Oxytocin agonist | 0.064 0.014 DBMET00621 0.059 0.018 DBMET00634 | DBMET00621 | |
| 0.094 | 0.049 | 0.135 | 5 Hydroxytryptamine 2C antagonist | 0.135 0.031 DBMET00621 0.123 0.035 DBMET00634 | DBMET00621 | |
| 0.099 | 0.055 | 0.324 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.324 0.005 DBMET00621 0.157 0.024 DBMET00634 | DBMET00621 | |
| 0.056 | 0.012 | 0.085 | Histamine H1 receptor agonist | 0.085 0.003 DBMET00621 0.081 0.004 DBMET00634 | DBMET00621 | |
| 0.055 | 0.011 | 0.428 | Baculoviral IAP repeat-containing protein inhibitor | 0.055 0.01 DBMET00621 0.428 0.002 DBMET00634 | DBMET00634 | |
| 0.084 | 0.04 | 0.597 | 5 Hydroxytryptamine 1F antagonist | 0.597 0.004 DBMET00621 0.233 0.008 DBMET00634 | DBMET00621 | |
| 0.209 | 0.166 | 0.336 | Antithrombotic | 0.336 0.07 DBMET00621 0.319 0.077 DBMET00634 | DBMET00621 | |
| 0.138 | 0.095 | 0.138 | Sigma receptor agonist | |||
| 0.075 | 0.032 | 0.124 | NMDA receptor agonist | 0.124 0.012 DBMET00621 0.108 0.016 DBMET00634 | DBMET00621 | |
| 0.054 | 0.012 | 0.074 | Growth hormone releasing factor agonist | 0.074 0.006 DBMET00621 0.061 0.009 DBMET00634 | DBMET00621 | |
| 0.103 | 0.062 | 0.144 | Factor V inhibitor | 0.144 0.021 DBMET00621 0.113 0.046 DBMET00634 | DBMET00621 | |
| 0.1 | 0.059 | 0.19 | Creatine kinase inhibitor | 0.19 0.012 DBMET00621 0.154 0.022 DBMET00634 | DBMET00621 | |
| 0.087 | 0.046 | 0.1 | Glycine receptor antagonist | 0.1 0.032 DBMET00621 0.091 0.041 DBMET00634 | DBMET00621 | |
| 0.098 | 0.058 | 0.14 | Lanosterol 14 alpha demethylase inhibitor | 0.14 0.016 DBMET00621 0.115 0.035 DBMET00634 | DBMET00621 | |
| 0.067 | 0.028 | 0.091 | Sphingosine 1-phosphate receptor 3 antagonist | 0.091 0.011 DBMET00621 0.061 0.037 DBMET00634 | DBMET00621 | |
| 0.059 | 0.023 | 0.059 | Antiviral (Hepatitis D) | |||
| 0.1 | 0.063 | 0.131 | Anabolic | 0.131 0.03 DBMET00621 0.114 0.045 DBMET00634 | DBMET00621 | |
| 0.073 | 0.037 | 0.084 | Neutrophil collagenase inhibitor | 0.08 0.032 DBMET00621 0.084 0.029 DBMET00634 | DBMET00634 | |
| 0.083 | 0.047 | 0.131 | Nicotinic alpha4beta2 receptor antagonist | 0.108 0.025 DBMET00621 0.131 0.013 DBMET00634 | DBMET00634 | |
| 0.046 | 0.01 | 0.08 | Endothelial nitric-oxide synthase inhibitor | 0.08 0.005 DBMET00621 0.075 0.005 DBMET00634 | DBMET00621 | |
| 0.056 | 0.02 | 0.057 | Collagenase inhibitor | 0.05 0.032 DBMET00621 0.057 0.019 DBMET00634 | DBMET00634 | |
| 0.067 | 0.032 | 0.081 | Cathepsin E inhibitor | 0.081 0.022 DBMET00621 0.072 0.028 DBMET00634 | DBMET00621 | |
| 0.086 | 0.05 | 0.086 | Neuropeptide Y antagonist | 0.074 0.069 DBMET00621 | ||
| 0.067 | 0.033 | 0.067 | Acetylcholine M5 receptor antagonist | |||
| 0.105 | 0.071 | 0.175 | Mucolytic | 0.175 0.021 DBMET00621 0.125 0.05 DBMET00634 | DBMET00621 | |
| 0.08 | 0.047 | 0.159 | GABA aminotransferase inhibitor | 0.159 0.006 DBMET00621 0.089 0.036 DBMET00634 | DBMET00621 | |
| 0.244 | 0.212 | 0.503 | Calcium channel L-type activator | 0.408 0.076 DBMET00621 0.503 0.026 DBMET00634 | DBMET00634 | |
| 0.066 | 0.034 | 0.125 | Bombesin 1 receptor agonist | 0.125 0.012 DBMET00621 0.096 0.019 DBMET00634 | DBMET00621 | |
| 0.076 | 0.044 | 0.107 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.107 0.01 DBMET00621 0.082 0.033 DBMET00634 | DBMET00621 | |
| 0.07 | 0.039 | 0.128 | 5 Hydroxytryptamine uptake inhibitor | 0.082 0.033 DBMET00621 0.128 0.019 DBMET00634 | DBMET00634 | |
| 0.046 | 0.015 | 0.046 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | |||
| 0.085 | 0.055 | 0.093 | Histamine H2 receptor antagonist | 0.082 0.06 DBMET00621 0.093 0.043 DBMET00634 | DBMET00634 | |
| 0.057 | 0.026 | 0.091 | Bombesin 2 receptor antagonist | 0.091 0.015 DBMET00621 0.058 0.025 DBMET00634 | DBMET00621 | |
| 0.149 | 0.119 | 0.149 | P-glycoprotein inhibitor | |||
| 0.074 | 0.044 | 0.108 | Phospholipase D inhibitor | 0.094 0.019 DBMET00621 0.108 0.011 DBMET00634 | DBMET00634 | |
| 0.096 | 0.066 | 0.186 | Carbonic anhydrase III inhibitor | 0.186 0.019 DBMET00621 0.123 0.042 DBMET00634 | DBMET00621 | |
| 0.061 | 0.032 | 0.095 | Kallikrein 1 inhibitor | 0.095 0.013 DBMET00621 0.072 0.022 DBMET00634 | DBMET00621 | |
| 0.199 | 0.17 | 0.225 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.207 0.148 DBMET00621 0.225 0.106 DBMET00634 | DBMET00634 | |
| 0.042 | 0.013 | 0.077 | Dipeptidyl peptidase II inhibitor | 0.077 0.005 DBMET00621 0.044 0.012 DBMET00634 | DBMET00621 | |
| 0.036 | 0.008 | 0.036 | Myristoyl transferase inhibitor | 0.026 0.021 DBMET00621 0.028 0.018 DBMET00634 | ||
| 0.073 | 0.045 | 0.118 | Secretase beta inhibitor | 0.118 0.011 DBMET00621 0.084 0.032 DBMET00634 | DBMET00621 | |
| 0.056 | 0.028 | 0.056 | Vanilloid 2 antagonist | 0.056 0.029 DBMET00621 | ||
| 0.062 | 0.035 | 0.117 | Sphingosine kinase inhibitor | 0.117 0.005 DBMET00621 0.089 0.011 DBMET00634 | DBMET00621 | |
| 0.09 | 0.062 | 0.122 | Glutamate release inhibitor | 0.122 0.02 DBMET00621 0.115 0.025 DBMET00634 | DBMET00621 | |
| 0.058 | 0.031 | 0.102 | Opioid agonist | 0.102 0.013 DBMET00621 0.058 0.032 DBMET00634 | DBMET00621 | |
| 0.046 | 0.019 | 0.104 | Kainate receptor agonist | 0.104 0.003 DBMET00621 0.057 0.008 DBMET00634 | DBMET00621 | |
| 0.086 | 0.059 | 0.086 | Alpha 2 adrenoreceptor antagonist | |||
| 0.055 | 0.028 | 0.076 | Lysophosphatidic acid 3 receptor antagonist | 0.076 0.011 DBMET00621 0.072 0.013 DBMET00634 | DBMET00621 | |
| 0.079 | 0.053 | 0.091 | Interferon agonist | 0.091 0.037 DBMET00621 0.071 0.068 DBMET00634 | DBMET00621 | |
| 0.058 | 0.031 | 0.058 | Neuropeptide Y5 antagonist | |||
| 0.054 | 0.029 | 0.054 | Neurokinin antagonist | |||
| 0.039 | 0.014 | 0.044 | Adenosine uptake inhibitor | 0.044 0.007 DBMET00621 0.041 0.011 DBMET00634 | DBMET00621 | |
| 0.067 | 0.042 | 0.195 | Opioid delta receptor antagonist | 0.195 0.012 DBMET00621 0.107 0.029 DBMET00634 | DBMET00621 | |
| 0.054 | 0.029 | 0.106 | Dopamine transporter inhibitor | 0.106 0.01 DBMET00621 0.071 0.02 DBMET00634 | DBMET00621 | |
| 0.046 | 0.022 | 0.046 | Neurokinin 1 antagonist | |||
| 0.136 | 0.112 | 0.168 | Antipruritic | 0.166 0.077 DBMET00621 0.168 0.075 DBMET00634 | DBMET00634 | |
| 0.034 | 0.01 | 0.043 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.037 0.008 DBMET00621 0.043 0.006 DBMET00634 | DBMET00634 | |
| 0.063 | 0.04 | 0.065 | Prolactin release inhibitor | 0.065 0.035 DBMET00621 | DBMET00621 | |
| 0.048 | 0.025 | 0.065 | Geranyltranstransferase inhibitor | 0.065 0.01 DBMET00621 0.059 0.014 DBMET00634 | DBMET00621 | |
| 0.032 | 0.009 | 0.053 | Growth hormone release promoting | 0.053 0.005 DBMET00621 0.046 0.006 DBMET00634 | DBMET00621 | |
| 0.037 | 0.014 | 0.038 | Lysophosphatidic acid 2 receptor antagonist | 0.038 0.014 DBMET00621 0.033 0.018 DBMET00634 | DBMET00621 | |
| 0.108 | 0.085 | 0.143 | Aldehyde dehydrogenase inhibitor | 0.143 0.052 DBMET00621 0.106 0.088 DBMET00634 | DBMET00621 | |
| 0.043 | 0.02 | 0.153 | 5 Hydroxytryptamine 2B agonist | 0.153 0.003 DBMET00621 0.053 0.011 DBMET00634 | DBMET00621 | |
| 0.03 | 0.009 | 0.033 | Acid ceramidase inhibitor | 0.031 0.008 DBMET00621 0.033 0.006 DBMET00634 | DBMET00634 | |
| 0.063 | 0.042 | 0.085 | NMDA receptor glycine site agonist | 0.085 0.025 DBMET00621 | DBMET00621 | |
| 0.068 | 0.047 | 0.113 | Glutamate (mGluR7) antagonist | 0.113 0.005 DBMET00621 0.076 0.032 DBMET00634 | DBMET00621 | |
| 0.03 | 0.009 | 0.041 | Vanilloid 2 agonist | 0.041 0.004 DBMET00621 0.038 0.004 DBMET00634 | DBMET00621 | |
| 0.211 | 0.19 | 0.408 | Histamine release inhibitor | 0.408 0.072 DBMET00621 0.378 0.087 DBMET00634 | DBMET00621 | |
| 0.046 | 0.026 | 0.102 | Histamine H2 receptor agonist | 0.097 0.004 DBMET00621 0.102 0.004 DBMET00634 | DBMET00634 | |
| 0.067 | 0.047 | 0.098 | Neuronal nicotinic receptor antagonist | 0.071 0.044 DBMET00621 0.098 0.025 DBMET00634 | DBMET00634 | |
| 0.065 | 0.046 | 0.121 | Beta adrenoreceptor antagonist | 0.076 0.03 DBMET00621 0.121 0.01 DBMET00634 | DBMET00634 | |
| 0.11 | 0.09 | 0.179 | Toll-Like receptor 2 antagonist | 0.179 0.034 DBMET00621 0.114 0.084 DBMET00634 | DBMET00621 | |
| 0.077 | 0.058 | 0.138 | Chymotrypsin inhibitor | 0.138 0.02 DBMET00621 0.093 0.041 DBMET00634 | DBMET00621 | |
| 0.03 | 0.012 | 0.03 | Hedgehog signaling activator | 0.027 0.021 DBMET00621 0.026 0.023 DBMET00634 | ||
| 0.054 | 0.036 | 0.07 | Alpha-mannosidase inhibitor | 0.07 0.016 DBMET00621 0.056 0.033 DBMET00634 | DBMET00621 | |
| 0.084 | 0.066 | 0.142 | Granulocyte macrophage colony stimulating factor agonist | 0.142 0.007 DBMET00621 0.117 0.018 DBMET00634 | DBMET00621 | |
| 0.062 | 0.044 | 0.074 | Trypsin inhibitor | 0.074 0.03 DBMET00621 0.065 0.039 DBMET00634 | DBMET00621 | |
| 0.041 | 0.023 | 0.041 | CF transmembrane conductance regulator antagonist | |||
| 0.035 | 0.017 | 0.036 | Peptide deformylase inhibitor | 0.032 0.019 DBMET00621 0.036 0.016 DBMET00634 | DBMET00634 | |
| 0.033 | 0.015 | 0.053 | Thrombin receptor antagonist | 0.053 0.008 DBMET00621 0.034 0.014 DBMET00634 | DBMET00621 | |
| 0.055 | 0.037 | 0.085 | Acyl-CoA dehydrogenase inhibitor | 0.085 0.02 DBMET00621 0.064 0.03 DBMET00634 | DBMET00621 | |
| 0.061 | 0.044 | 0.097 | NMDA 2C receptor antagonist | 0.097 0.017 DBMET00621 | DBMET00621 | |
| 0.056 | 0.039 | 0.059 | 5 Hydroxytryptamine 7 agonist | 0.059 0.032 DBMET00621 0.058 0.034 DBMET00634 | DBMET00621 | |
| 0.074 | 0.057 | 0.093 | GABA B receptor agonist | 0.093 0.022 DBMET00621 | DBMET00621 | |
| 0.036 | 0.02 | 0.036 | Benzodiazepine receptor peripheral-type antagonist | |||
| 0.156 | 0.14 | 0.268 | Antiamyloidogenic | 0.268 0.063 DBMET00621 0.202 0.098 DBMET00634 | DBMET00621 | |
| 0.03 | 0.014 | 0.039 | Motilin receptor antagonist | 0.037 0.009 DBMET00621 0.039 0.008 DBMET00634 | DBMET00634 | |
| 0.042 | 0.027 | 0.086 | Sphingosine kinase 1 inhibitor | 0.086 0.005 DBMET00621 0.062 0.008 DBMET00634 | DBMET00621 | |
| 0.039 | 0.024 | 0.039 | Somatostatin 4 agonist | |||
| 0.026 | 0.011 | 0.026 | Neurokinin 1 agonist | 0.025 0.012 DBMET00621 0.022 0.013 DBMET00634 | ||
| 0.024 | 0.01 | 0.024 | Lysophosphatidic acid 1 receptor antagonist | |||
| 0.053 | 0.039 | 0.091 | Ribonucleoside-diphosphate reductase inhibitor | 0.091 0.021 DBMET00621 0.073 0.028 DBMET00634 | DBMET00621 | |
| 0.022 | 0.008 | 0.024 | Estrogen-related receptor gamma agonist | 0.019 0.012 DBMET00621 0.024 0.006 DBMET00634 | DBMET00634 | |
| 0.054 | 0.04 | 0.125 | Sphingosine kinase 2 inhibitor | 0.125 0.004 DBMET00621 0.091 0.01 DBMET00634 | DBMET00621 | |
| 0.057 | 0.044 | 0.141 | Carbonic anhydrase stimulant | 0.141 0.012 DBMET00621 0.111 0.016 DBMET00634 | DBMET00621 | |
| 0.031 | 0.018 | 0.031 | 5 Hydroxytryptamine 1D agonist | |||
| 0.039 | 0.025 | 0.049 | Potassium channel Kv1.1 blocker | 0.046 0.016 DBMET00621 0.049 0.014 DBMET00634 | DBMET00634 | |
| 0.054 | 0.041 | 0.099 | Beta 1 adrenoreceptor antagonist | 0.071 0.025 DBMET00621 0.099 0.01 DBMET00634 | DBMET00634 | |
| 0.07 | 0.057 | 0.184 | Glutamate dehydrogenase inhibitor | 0.184 0.011 DBMET00621 0.149 0.016 DBMET00634 | DBMET00621 | |
| 0.053 | 0.041 | 0.08 | Epithelial sodium channel blocker | 0.08 0.012 DBMET00621 0.061 0.028 DBMET00634 | DBMET00621 | |
| 0.047 | 0.034 | 0.061 | Bombesin antagonist | 0.061 0.017 DBMET00621 0.048 0.032 DBMET00634 | DBMET00621 | |
| 0.029 | 0.017 | 0.029 | Estrogen-related receptor gamma antagonist | 0.027 0.025 DBMET00621 0.029 0.018 DBMET00634 | ||
| 0.052 | 0.04 | 0.078 | Cathepsin D inhibitor | 0.078 0.026 DBMET00621 0.059 0.035 DBMET00634 | DBMET00621 | |
| 0.059 | 0.046 | 0.059 | Enoyl-[acyl-carrier-protein] reductase inhibitor | |||
| 0.109 | 0.097 | 0.176 | Sphingosine 1-phosphate receptor 4 antagonist | 0.176 0.016 DBMET00621 0.115 0.082 DBMET00634 | DBMET00621 | |
| 0.116 | 0.104 | 0.473 | Peroxidase inhibitor | 0.473 0.012 DBMET00621 0.16 0.073 DBMET00634 | DBMET00621 | |
| 0.025 | 0.013 | 0.025 | Geranylgeranyltransferase inhibitor | 0.022 0.016 DBMET00621 | ||
| 0.051 | 0.039 | 0.1 | Dipeptidyl peptidase inhibitor | 0.1 0.009 DBMET00621 0.067 0.019 DBMET00634 | DBMET00621 | |
| 0.095 | 0.084 | 0.182 | Nav1.4 sodium channel blocker | 0.182 0.023 DBMET00621 0.111 0.061 DBMET00634 | DBMET00621 | |
| 0.031 | 0.019 | 0.031 | Complement C5a chemotactic receptor antagonist | |||
| 0.052 | 0.041 | 0.091 | Ribonucleotide reductase inhibitor | 0.091 0.023 DBMET00621 0.075 0.029 DBMET00634 | DBMET00621 | |
| 0.055 | 0.044 | 0.078 | Cathepsin L inhibitor | 0.078 0.026 DBMET00621 0.074 0.027 DBMET00634 | DBMET00621 | |
| 0.062 | 0.051 | 0.062 | Dopamine agonist | |||
| 0.036 | 0.026 | 0.065 | Arginase inhibitor | 0.065 0.009 DBMET00621 0.043 0.02 DBMET00634 | DBMET00621 | |
| 0.031 | 0.021 | 0.097 | Dipeptidyl peptidase I inhibitor | 0.097 0.004 DBMET00621 0.059 0.007 DBMET00634 | DBMET00621 | |
| 0.044 | 0.035 | 0.047 | Adenylate cyclase 1 inhibitor | 0.047 0.031 DBMET00621 0.046 0.032 DBMET00634 | DBMET00621 | |
| 0.061 | 0.051 | 0.075 | Interferon inducer | 0.075 0.029 DBMET00621 0.059 0.057 DBMET00634 | DBMET00621 | |
| 0.014 | 0.004 | 0.014 | Angiotensin AT2 receptor agonist | 0.011 0.006 DBMET00621 | ||
| 0.048 | 0.039 | 0.088 | Beta 2 adrenoreceptor antagonist | 0.063 0.021 DBMET00621 0.088 0.009 DBMET00634 | DBMET00634 | |
| 0.081 | 0.072 | 0.119 | Falcipain inhibitor | 0.119 0.045 DBMET00621 0.085 0.068 DBMET00634 | DBMET00621 | |
| 0.074 | 0.065 | 0.093 | MAP kinase kinase 7 inhibitor | 0.093 0.02 DBMET00621 0.084 0.037 DBMET00634 | DBMET00621 | |
| 0.125 | 0.116 | 0.217 | GABA C receptor rho-2 antagonist | 0.173 0.048 DBMET00621 0.217 0.021 DBMET00634 | DBMET00634 | |
| 0.035 | 0.027 | 0.052 | Histone deacetylase 7 inhibitor | 0.052 0.018 DBMET00634 | DBMET00634 | |
| 0.081 | 0.073 | 0.13 | NADH dehydrogenase inhibitor | 0.13 0.024 DBMET00621 0.092 0.054 DBMET00634 | DBMET00621 | |
| 0.026 | 0.018 | 0.03 | Integrin alpha2beta1 antagonist | 0.025 0.02 DBMET00621 0.03 0.013 DBMET00634 | DBMET00634 | |
| 0.068 | 0.06 | 0.084 | Metalloproteinase-9 inhibitor | 0.072 0.052 DBMET00621 0.084 0.041 DBMET00634 | DBMET00634 | |
| 0.038 | 0.031 | 0.094 | Dopamine D5 agonist | 0.094 0.005 DBMET00621 0.054 0.015 DBMET00634 | DBMET00621 | |
| 0.047 | 0.04 | 0.069 | Matrix metalloproteinase 1 inhibitor | 0.054 0.036 DBMET00621 0.069 0.026 DBMET00634 | DBMET00634 | |
| 0.018 | 0.011 | 0.032 | Tryptophan hydroxylase 1 inhibitor | 0.032 0.003 DBMET00621 0.017 0.012 DBMET00634 | DBMET00621 | |
| 0.088 | 0.081 | 0.179 | GABA C receptor rho-1 antagonist | 0.179 0.012 DBMET00621 0.171 0.014 DBMET00634 | DBMET00621 | |
| 0.097 | 0.091 | 0.098 | Cholesterol synthesis inhibitor | 0.098 0.09 DBMET00621 | DBMET00621 | |
| 0.044 | 0.037 | 0.064 | Beta adrenoreceptor agonist | 0.052 0.014 DBMET00621 0.064 0.007 DBMET00634 | DBMET00634 | |
| 0.024 | 0.018 | 0.1 | Glutamate (mGluR1) agonist | 0.1 0.004 DBMET00621 0.036 0.007 DBMET00634 | DBMET00621 | |
| 0.078 | 0.072 | 0.113 | Falcipain 2 inhibitor | 0.113 0.045 DBMET00621 0.081 0.068 DBMET00634 | DBMET00621 | |
| 0.079 | 0.073 | 0.091 | 3C-Like protease (SARS coronavirus) inhibitor | 0.091 0.044 DBMET00621 0.086 0.054 DBMET00634 | DBMET00621 | |
| 0.053 | 0.048 | 0.053 | CXC chemokine 4 receptor antagonist | |||
| 0.033 | 0.028 | 0.066 | Opioid delta receptor agonist | 0.066 0.008 DBMET00621 | DBMET00621 | |
| 0.028 | 0.024 | 0.028 | Acetylcholine M4 receptor agonist | |||
| 0.045 | 0.04 | 0.061 | Metalloproteinase-3 inhibitor | 0.05 0.033 DBMET00621 0.061 0.023 DBMET00634 | DBMET00634 | |
| 0.055 | 0.051 | 0.056 | Gonadotropin-releasing hormone receptor agonist | 0.056 0.048 DBMET00621 | DBMET00621 | |
| 0.034 | 0.031 | 0.04 | Integrin alpha2 antagonist | 0.034 0.031 DBMET00621 0.04 0.02 DBMET00634 | DBMET00634 | |
| 0.065 | 0.061 | 0.214 | Glutamate decarboxylase inhibitor | 0.214 0.006 DBMET00621 0.089 0.037 DBMET00634 | DBMET00621 | |
| 0.029 | 0.026 | 0.029 | LIM domain kinase 2 inhibitor | |||
| 0.041 | 0.038 | 0.077 | Dipeptidyl peptidase IV inhibitor | 0.077 0.008 DBMET00621 0.05 0.02 DBMET00634 | DBMET00621 | |
| 0.1 | 0.097 | 0.183 | Interleukin 8 antagonist | 0.174 0.021 DBMET00621 0.183 0.018 DBMET00634 | DBMET00634 | |
| 0.086 | 0.083 | 0.119 | 5 Hydroxytryptamine 2 antagonist | 0.119 0.059 DBMET00621 0.115 0.062 DBMET00634 | DBMET00621 | |
| 0.021 | 0.018 | 0.024 | Motilin receptor agonist | 0.024 0.014 DBMET00634 | DBMET00634 | |
| 0.08 | 0.078 | 0.08 | Antihistaminic | |||
| 0.042 | 0.039 | 0.042 | Thymidylate synthase inhibitor | |||
| 0.069 | 0.067 | 0.076 | Potassium channel (Tandem pore domain) blocker | 0.076 0.044 DBMET00621 0.076 0.045 DBMET00634 | DBMET00634 | |
| 0.107 | 0.105 | 0.113 | DNA repair enzyme inhibitor | 0.113 0.088 DBMET00621 | DBMET00621 | |
| 0.02 | 0.018 | 0.149 | Baculoviral IAP repeat-containing protein 3 inhibitor | 0.149 0.002 DBMET00634 | DBMET00634 | |
| 0.033 | 0.031 | 0.042 | Ceramide glucosyltransferase inhibitor | 0.038 0.02 DBMET00621 0.042 0.014 DBMET00634 | DBMET00634 | |
| 0.033 | 0.032 | 0.059 | Melanocortin 1 antagonist | 0.059 0.017 DBMET00621 0.044 0.022 DBMET00634 | DBMET00621 | |
| 0.038 | 0.037 | 0.041 | Angiotensin AT1 receptor antagonist | 0.041 0.031 DBMET00621 | DBMET00621 | |
| 0.014 | 0.013 | 0.017 | CXC chemokine 4 receptor agonist | 0.017 0.009 DBMET00621 | DBMET00621 | |
| 0.058 | 0.057 | 0.083 | Histone deacetylase SIRT3 inhibitor | 0.083 0.016 DBMET00621 0.076 0.022 DBMET00634 | DBMET00621 | |
| 0.028 | 0.028 | 0.029 | Trypsin I inhibitor | 0.029 0.027 DBMET00621 | DBMET00621 | |
| 0.05 | 0.05 | 0.068 | Cathepsin B inhibitor | 0.068 0.03 DBMET00621 0.065 0.032 DBMET00634 | DBMET00621 | |
| 0.057 | 0.058 | 0.083 | Matrix metalloproteinase inhibitor | 0.07 0.044 DBMET00621 0.083 0.035 DBMET00634 | DBMET00634 | |
| 0.033 | 0.033 | 0.041 | Cholecystokinin B agonist | 0.041 0.022 DBMET00621 | DBMET00621 | |
| 0.04 | 0.04 | 0.061 | Mannosidase inhibitor | 0.061 0.016 DBMET00621 0.042 0.036 DBMET00634 | DBMET00621 | |
| 0.078 | 0.078 | 0.084 | Vanilloid agonist | 0.084 0.06 DBMET00621 | DBMET00621 | |
| 0.023 | 0.024 | 0.029 | Urotensin II agonist | 0.029 0.016 DBMET00621 0.028 0.017 DBMET00634 | DBMET00621 | |
| 0.03 | 0.031 | 0.036 | Angiotensin II receptor antagonist | 0.036 0.02 DBMET00621 | DBMET00621 | |
| 0.02 | 0.021 | 0.054 | Aminopeptidase P inhibitor | 0.054 0.004 DBMET00621 0.026 0.013 DBMET00634 | DBMET00621 | |
| 0.145 | 0.146 | 0.243 | Neurotrophic factor enhancer | 0.243 0.042 DBMET00621 0.228 0.053 DBMET00634 | DBMET00621 | |
| 0.019 | 0.021 | 0.031 | Neuraminidase (Influenza B) inhibitor | 0.031 0.004 DBMET00621 0.024 0.009 DBMET00634 | DBMET00621 | |
| 0.026 | 0.028 | 0.035 | Purinergic P2Y15 antagonist | 0.035 0.01 DBMET00621 0.033 0.013 DBMET00634 | DBMET00621 | |
| 0.041 | 0.044 | 0.045 | CC chemokine 4 receptor antagonist | 0.045 0.036 DBMET00634 | DBMET00634 | |
| 0.035 | 0.037 | 0.041 | Histone deacetylase 9 inhibitor | 0.041 0.024 DBMET00634 | DBMET00634 | |
| 0.124 | 0.126 | 0.18 | Melanin inhibitor | 0.18 0.051 DBMET00621 0.135 0.105 DBMET00634 | DBMET00621 | |
| 0.017 | 0.019 | 0.034 | Integrin alpha4beta7 antagonist | 0.034 0.008 DBMET00621 0.034 0.008 DBMET00634 | DBMET00634 | |
| 0.039 | 0.042 | 0.124 | Opioid mu receptor agonist | 0.124 0.009 DBMET00621 0.055 0.026 DBMET00634 | DBMET00621 | |
| 0.12 | 0.124 | 0.194 | Sphingosine 1-phosphate receptor 5 antagonist | 0.194 0.014 DBMET00621 0.14 0.08 DBMET00634 | DBMET00621 | |
| 0.033 | 0.037 | 0.041 | Erythropoietin receptor agonist | 0.041 0.028 DBMET00621 0.039 0.03 DBMET00634 | DBMET00621 | |
| 0.085 | 0.089 | 0.218 | Nav1.1 sodium channel blocker | 0.093 0.076 DBMET00621 0.218 0.016 DBMET00634 | DBMET00634 | |
| 0.011 | 0.015 | 0.012 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.012 0.011 DBMET00621 | DBMET00621 | |
| 0.013 | 0.018 | 0.034 | Aminopeptidase A inhibitor | 0.034 0.005 DBMET00621 0.029 0.006 DBMET00634 | DBMET00621 | |
| 0.021 | 0.026 | 0.032 | Lysophosphatidic acid receptor 1 agonist | 0.032 0.009 DBMET00621 0.031 0.01 DBMET00634 | DBMET00621 | |
| 0.094 | 0.099 | 0.13 | TRPA1 agonist | 0.13 0.048 DBMET00621 0.108 0.074 DBMET00634 | DBMET00621 | |
| 0.045 | 0.05 | 0.104 | Histamine agonist | 0.088 0.011 DBMET00621 0.104 0.008 DBMET00634 | DBMET00634 | |
| 0.05 | 0.056 | 0.073 | Botulinum neurotoxin type A inhibitor | 0.073 0.023 DBMET00621 0.054 0.048 DBMET00634 | DBMET00621 | |
| 0.029 | 0.035 | 0.036 | Calpain 1 inhibitor | 0.036 0.016 DBMET00621 0.033 0.023 DBMET00634 | DBMET00621 | |
| 0.095 | 0.101 | 0.162 | Cell adhesion inhibitor | 0.162 0.04 DBMET00621 0.139 0.053 DBMET00634 | DBMET00621 | |
| 0.047 | 0.053 | 0.095 | Bombesin 3 receptor antagonist | 0.095 0.013 DBMET00621 0.067 0.026 DBMET00634 | DBMET00621 | |
| 0.055 | 0.06 | 0.08 | Corticotropin releasing factor 2 receptor antagonist | 0.08 0.017 DBMET00621 0.067 0.033 DBMET00634 | DBMET00621 | |
| 0.032 | 0.038 | 0.054 | Cathepsin L1 inhibitor | 0.054 0.018 DBMET00621 0.053 0.018 DBMET00634 | DBMET00621 | |
| 0.007 | 0.014 | 0.01 | Melatonin 5 antagonist | 0.01 0.009 DBMET00621 | DBMET00621 | |
| 0.033 | 0.04 | 0.038 | GABA uptake inhibitor | 0.038 0.029 DBMET00621 | DBMET00621 | |
| 0.008 | 0.015 | 0.166 | Baculoviral IAP repeat-containing protein 2 inhibitor | 0.166 0.002 DBMET00634 | DBMET00634 | |
| 0.014 | 0.021 | 0.028 | Histamine H4 receptor agonist | 0.028 0.007 DBMET00621 0.025 0.008 DBMET00634 | DBMET00621 | |
| 0.036 | 0.044 | 0.064 | Nicotinic receptor alpha3 subunit antagonist | 0.064 0.017 DBMET00621 0.047 0.027 DBMET00634 | DBMET00621 | |
| 0.021 | 0.029 | 0.052 | AMPA 3 receptor antagonist | 0.052 0.008 DBMET00621 0.028 0.022 DBMET00634 | DBMET00621 | |
| 0.028 | 0.037 | 0.031 | Vanilloid 4 antagonist | 0.031 0.027 DBMET00634 | DBMET00634 | |
| 0.011 | 0.02 | 0.015 | NMDA receptor phencyclidine site antagonist | 0.015 0.01 DBMET00634 | DBMET00634 | |
| 0.013 | 0.022 | 0.017 | Cyclin T1 inhibitor | 0.017 0.015 DBMET00621 | DBMET00621 | |
| 0.022 | 0.032 | 0.041 | Nicotinic alpha4beta2 receptor agonist | 0.041 0.007 DBMET00634 | DBMET00634 | |
| 0.025 | 0.035 | 0.053 | Calcitonin receptor agonist | 0.053 0.016 DBMET00621 0.039 0.021 DBMET00634 | DBMET00621 | |
| 0.065 | 0.075 | 0.085 | Metalloproteinase-2 inhibitor | 0.081 0.052 DBMET00621 0.085 0.047 DBMET00634 | DBMET00634 | |
| 0.094 | 0.103 | 0.146 | Microtubule formation inhibitor | 0.137 0.045 DBMET00621 0.146 0.039 DBMET00634 | DBMET00634 | |
| 0.039 | 0.049 | 0.096 | NMDA 2A receptor antagonist | 0.096 0.014 DBMET00621 0.096 0.014 DBMET00634 | DBMET00634 | |
| 0.035 | 0.045 | 0.048 | HIV-1 protease inhibitor | 0.048 0.023 DBMET00621 0.042 0.032 DBMET00634 | DBMET00621 | |
| 0.028 | 0.039 | 0.043 | Bombesin 1 receptor antagonist | 0.043 0.019 DBMET00621 0.038 0.025 DBMET00634 | DBMET00621 | |
| 0.043 | 0.054 | 0.063 | Cytokine production stimulant | 0.063 0.011 DBMET00621 0.047 0.039 DBMET00634 | DBMET00621 | |
| 0.082 | 0.094 | 0.155 | Expectorant | 0.155 0.033 DBMET00621 0.102 0.066 DBMET00634 | DBMET00621 | |
| 0.024 | 0.036 | 0.026 | Glucosylceramidase stimulant | 0.026 0.022 DBMET00634 | DBMET00634 | |
| 0.2 | 0.213 | 0.315 | Calcium channel activator | 0.315 0.077 DBMET00621 0.308 0.084 DBMET00634 | DBMET00621 | |
| 0.043 | 0.056 | 0.122 | Aminopeptidase microsomal inhibitor | 0.122 0.013 DBMET00621 0.069 0.032 DBMET00634 | DBMET00621 | |
| 0.03 | 0.043 | 0.066 | Toll-Like receptor 2 agonist | 0.066 0.019 DBMET00621 0.041 0.029 DBMET00634 | DBMET00621 | |
| 0.012 | 0.025 | 0.028 | Integrin beta7 antagonist | 0.028 0.01 DBMET00621 0.022 0.013 DBMET00634 | DBMET00621 | |
| 0.043 | 0.057 | 0.206 | Argininosuccinate synthase inhibitor | 0.206 0.007 DBMET00621 0.076 0.027 DBMET00634 | DBMET00621 | |
| 0.015 | 0.029 | 0.02 | Antibiotic Anthracycline-like | 0.02 0.011 DBMET00621 | DBMET00621 | |
| 0.036 | 0.05 | 0.046 | AICAR transformylase inhibitor | 0.046 0.027 DBMET00621 0.04 0.038 DBMET00634 | DBMET00621 | |
| 0.044 | 0.059 | 0.064 | Matrix metalloproteinase (membrane-type) inhibitor | 0.057 0.035 DBMET00621 0.064 0.029 DBMET00634 | DBMET00634 | |
| 0.026 | 0.041 | 0.034 | GHS receptor antagonist | 0.034 0.019 DBMET00621 0.031 0.024 DBMET00634 | DBMET00621 | |
| 0.022 | 0.037 | 0.028 | Somatostatin agonist | 0.028 0.026 DBMET00621 | DBMET00621 | |
| 0.078 | 0.094 | 0.135 | UDP-glucose 4-epimerase inhibitor | 0.135 0.035 DBMET00621 0.106 0.055 DBMET00634 | DBMET00621 | |
| 0.05 | 0.067 | 0.086 | 5 Hydroxytryptamine 1B antagonist | 0.086 0.031 DBMET00634 | DBMET00634 | |
| 0.007 | 0.024 | 0.015 | Lysophosphatidic acid receptor 3 agonist | 0.015 0.008 DBMET00621 | DBMET00621 | |
| 0.029 | 0.046 | 0.04 | Histone deacetylase 8 inhibitor | 0.04 0.03 DBMET00621 | DBMET00621 | |
| 0.04 | 0.058 | 0.059 | Dopamine beta hydroxylase inhibitor | 0.059 0.017 DBMET00621 0.047 0.038 DBMET00634 | DBMET00621 | |
| 0.045 | 0.063 | 0.068 | Angiotensin-converting enzyme inhibitor | 0.068 0.022 DBMET00621 0.056 0.036 DBMET00634 | DBMET00621 | |
| 0.055 | 0.072 | 0.226 | Catalase inhibitor | 0.226 0.011 DBMET00621 0.124 0.032 DBMET00634 | DBMET00621 | |
| 0.119 | 0.137 | 0.182 | Interferon gamma antagonist | 0.182 0.049 DBMET00621 0.146 0.083 DBMET00634 | DBMET00621 | |
| 0.026 | 0.044 | 0.038 | Carboxypeptidase B inhibitor | 0.038 0.014 DBMET00621 | DBMET00621 | |
| 0.05 | 0.068 | 0.134 | Sphingosine 1-phosphate receptor 4 agonist | 0.134 0.012 DBMET00621 0.085 0.033 DBMET00634 | DBMET00621 | |
| 0.027 | 0.045 | 0.071 | Complement C3a chemotactic receptor antagonist | 0.071 0.017 DBMET00621 | DBMET00621 | |
| 0.035 | 0.054 | 0.048 | Cathepsin F inhibitor | 0.048 0.015 DBMET00621 0.046 0.019 DBMET00634 | DBMET00621 | |
| 0.021 | 0.04 | 0.045 | Trypsin II inhibitor | 0.045 0.011 DBMET00621 | DBMET00621 | |
| 0.016 | 0.036 | 0.02 | Toll-Like receptor 8 agonist | 0.02 0.014 DBMET00621 | DBMET00621 | |
| 0.014 | 0.033 | 0.048 | Integrin alpha4 antagonist | 0.048 0.012 DBMET00621 0.03 0.016 DBMET00634 | DBMET00621 | |
| 0.01 | 0.03 | 0.037 | Dipeptidyl peptidase IX inhibitor | 0.037 0.005 DBMET00621 | DBMET00621 | |
| 0.031 | 0.051 | 0.049 | Sphingosine 1-phosphate receptor 1 agonist | 0.049 0.02 DBMET00621 | DBMET00621 | |
| 0.022 | 0.043 | 0.033 | 5 Hydroxytryptamine 6 agonist | 0.033 0.013 DBMET00621 | DBMET00621 | |
| 0.048 | 0.069 | 0.091 | Purinergic P2X1 antagonist | 0.091 0.02 DBMET00621 0.063 0.04 DBMET00634 | DBMET00621 | |
| 0.027 | 0.048 | 0.114 | Glutamate (mGluR3) antagonist | 0.114 0.004 DBMET00621 0.034 0.03 DBMET00634 | DBMET00621 | |
| 0.14 | 0.161 | 0.304 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.304 0.038 DBMET00621 | DBMET00621 | |
| 0.033 | 0.054 | 0.074 | GHS receptor agonist | 0.074 0.008 DBMET00621 0.048 0.022 DBMET00634 | DBMET00621 | |
| 0.034 | 0.056 | 0.056 | Melanocortin antagonist | 0.056 0.023 DBMET00621 0.05 0.03 DBMET00634 | DBMET00621 | |
| 0.029 | 0.051 | 0.053 | Melanocortin 4 antagonist | 0.053 0.022 DBMET00621 0.047 0.025 DBMET00634 | DBMET00621 | |
| 0.093 | 0.115 | 0.188 | Cyclooxygenase 3 inhibitor | 0.188 0.024 DBMET00621 0.139 0.058 DBMET00634 | DBMET00621 | |
| 0.044 | 0.066 | 0.14 | Carbamoyl phosphate synthetase inhibitor | 0.14 0.012 DBMET00621 0.062 0.041 DBMET00634 | DBMET00621 | |
| 0.026 | 0.049 | 0.051 | Glutamate (mGluR3) agonist | 0.051 0.005 DBMET00621 0.035 0.016 DBMET00634 | DBMET00621 | |
| 0.054 | 0.077 | 0.076 | Potassium channel (ATP-sensitive) blocker | 0.063 0.055 DBMET00621 0.076 0.033 DBMET00634 | DBMET00634 | |
| 0.03 | 0.054 | 0.082 | AMPA 4 receptor antagonist | 0.082 0.006 DBMET00621 0.043 0.022 DBMET00634 | DBMET00621 | |
| 0.057 | 0.08 | 0.13 | Glutamate (mGluR6) antagonist | 0.13 0.005 DBMET00621 0.07 0.039 DBMET00634 | DBMET00621 | |
| 0.035 | 0.059 | 0.131 | Ornithine carbamoyltransferase inhibitor | 0.131 0.011 DBMET00621 0.057 0.033 DBMET00634 | DBMET00621 | |
| 0.032 | 0.056 | 0.044 | Sphingosine 1-phosphate receptor agonist | 0.044 0.031 DBMET00621 | DBMET00621 | |
| 0.027 | 0.052 | 0.035 | Vascular adhesion protein 1 inhibitor | 0.035 0.033 DBMET00621 | DBMET00621 | |
| 0.011 | 0.036 | 0.02 | Human T-cell leukemia virus type I protease inhibitor | 0.02 0.016 DBMET00621 | DBMET00621 | |
| 0.022 | 0.048 | 0.054 | Methionyl aminopeptidase 1 inhibitor | 0.054 0.005 DBMET00621 | DBMET00621 | |
| 0.048 | 0.074 | 0.054 | Pregnane X receptor antagonist | 0.054 0.049 DBMET00621 | DBMET00621 | |
| 0.029 | 0.056 | 0.103 | Aminopeptidase N inhibitor | 0.103 0.012 DBMET00621 0.05 0.031 DBMET00634 | DBMET00621 | |
| 0.055 | 0.082 | 0.078 | 5 Hydroxytryptamine 2A antagonist | 0.078 0.06 DBMET00621 | DBMET00621 | |
| 0.024 | 0.051 | 0.077 | Kainate receptor antagonist | 0.077 0.01 DBMET00621 | DBMET00621 | |
| 0.044 | 0.071 | 0.062 | 5 Hydroxytryptamine 1D antagonist | 0.061 0.048 DBMET00621 0.062 0.046 DBMET00634 | DBMET00634 | |
| 0.023 | 0.05 | 0.068 | Cathepsin L2 inhibitor | 0.065 0.015 DBMET00621 0.068 0.014 DBMET00634 | DBMET00634 | |
| 0.066 | 0.093 | 0.111 | Glutathione S-transferase inhibitor | 0.111 0.028 DBMET00621 | DBMET00621 | |
| 0.155 | 0.181 | 0.247 | Peptidyltransferase inhibitor | 0.247 0.053 DBMET00621 0.239 0.059 DBMET00634 | DBMET00621 | |
| 0.015 | 0.042 | 0.03 | Beta 1 adrenoreceptor agonist | 0.022 0.017 DBMET00621 0.03 0.008 DBMET00634 | DBMET00634 | |
| 0.021 | 0.049 | 0.07 | Fumarate hydratase inhibitor | 0.07 0.008 DBMET00621 | DBMET00621 | |
| 0.023 | 0.051 | 0.065 | Somatostatin 1 antagonist | 0.065 0.013 DBMET00621 0.035 0.03 DBMET00634 | DBMET00621 | |
| 0.015 | 0.044 | 0.018 | Follicle-stimulating hormone antagonist | 0.018 0.017 DBMET00634 | DBMET00634 | |
| 0.044 | 0.073 | 0.121 | Alpha 2 adrenoreceptor agonist | 0.068 0.034 DBMET00621 0.121 0.01 DBMET00634 | DBMET00634 | |
| 0.045 | 0.075 | 0.055 | Sphingosine 1-phosphate receptor 1 antagonist | 0.055 0.04 DBMET00621 | DBMET00621 | |
| 0.028 | 0.058 | 0.052 | Membrane dipeptidase inhibitor | 0.052 0.014 DBMET00621 0.049 0.016 DBMET00634 | DBMET00621 | |
| 0.018 | 0.049 | 0.034 | Plasmepsin I inhibitor | 0.034 0.017 DBMET00621 | DBMET00621 | |
| 0.14 | 0.171 | 0.212 | Cyclic AMP phosphodiesterase inhibitor | 0.166 0.128 DBMET00621 0.212 0.085 DBMET00634 | DBMET00634 | |
| 0.017 | 0.048 | 0.037 | Renin inhibitor | 0.037 0.025 DBMET00621 0.033 0.029 DBMET00634 | DBMET00621 | |
| 0.015 | 0.047 | 0.03 | Isoleucine-tRNA ligase inhibitor | 0.03 0.005 DBMET00621 0.021 0.02 DBMET00634 | DBMET00621 | |
| 0.051 | 0.083 | 0.078 | Na+ K+ transporting ATPase inhibitor | 0.078 0.053 DBMET00621 | DBMET00621 | |
| 0.03 | 0.061 | 0.056 | Antimetabolite | 0.056 0.028 DBMET00621 | DBMET00621 | |
| 0.025 | 0.057 | 0.035 | Melatonin receptor 1A agonist | 0.035 0.02 DBMET00634 | DBMET00634 | |
| 0.033 | 0.065 | 0.047 | VCAM-1 antagonist | 0.045 0.015 DBMET00621 0.047 0.012 DBMET00634 | DBMET00634 | |
| 0.033 | 0.065 | 0.047 | VCAM antagonist | 0.044 0.015 DBMET00621 0.047 0.012 DBMET00634 | DBMET00634 | |
| 0.037 | 0.069 | 0.053 | Histamine H4 receptor antagonist | 0.053 0.026 DBMET00621 | DBMET00621 | |
| 0.029 | 0.061 | 0.069 | NMDA receptor subunit 3B antagonist | 0.069 0.016 DBMET00621 0.052 0.023 DBMET00634 | DBMET00621 | |
| 0.022 | 0.055 | 0.047 | Kinesin antagonist | 0.047 0.018 DBMET00621 | DBMET00621 | |
| 0.022 | 0.055 | 0.047 | Kinesin-like protein 1 inhibitor | 0.047 0.018 DBMET00621 | DBMET00621 | |
| 0.03 | 0.063 | 0.037 | Thymidine kinase inhibitor | 0.037 0.035 DBMET00621 | DBMET00621 | |
| 0.185 | 0.218 | 0.399 | Interleukin 2 agonist | 0.399 0.028 DBMET00621 0.255 0.113 DBMET00634 | DBMET00621 | |
| 0.039 | 0.073 | 0.097 | Glucagon-like peptide 1 agonist | 0.097 0.023 DBMET00621 0.056 0.051 DBMET00634 | DBMET00621 | |
| 0.081 | 0.115 | 0.121 | Protein kinase C gamma inhibitor | 0.121 0.052 DBMET00621 0.097 0.083 DBMET00634 | DBMET00621 | |
| 0.032 | 0.066 | 0.06 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.06 0.008 DBMET00621 0.041 0.03 DBMET00634 | DBMET00621 | |
| 0.063 | 0.097 | 0.096 | Myeloperoxidase inhibitor | 0.096 0.041 DBMET00621 | DBMET00621 | |
| 0.01 | 0.044 | 0.015 | Purinergic P2Y1 agonist | 0.015 0.011 DBMET00621 | DBMET00621 | |
| 0.069 | 0.103 | 0.136 | Triose-phosphate isomerase inhibitor | 0.136 0.024 DBMET00621 0.087 0.064 DBMET00634 | DBMET00621 | |
| 0.123 | 0.158 | 0.206 | 3C-like protease (Human coronavirus) inhibitor | 0.206 0.048 DBMET00621 0.172 0.072 DBMET00634 | DBMET00621 | |
| 0.041 | 0.076 | 0.176 | Protein kinase C iota inhibitor | 0.176 0.006 DBMET00621 0.071 0.031 DBMET00634 | DBMET00621 | |
| 0.009 | 0.044 | 0.016 | Nicotinic alpha4 receptor agonist | 0.016 0.012 DBMET00634 | DBMET00634 | |
| 0.043 | 0.078 | 0.069 | Cyclin A1 inhibitor | 0.069 0.023 DBMET00621 | DBMET00621 | |
| 0.026 | 0.062 | 0.056 | Growth hormone release inhibitor | 0.056 0.018 DBMET00621 0.038 0.033 DBMET00634 | DBMET00621 | |
| 0.028 | 0.064 | 0.047 | Leukocyte elastase inhibitor | 0.047 0.026 DBMET00621 | DBMET00621 | |
| 0.01 | 0.046 | 0.021 | Telomerase stimulant | 0.021 0.006 DBMET00621 | DBMET00621 | |
| 0.009 | 0.044 | 0.03 | Dipeptidyl peptidase VIII inhibitor | 0.03 0.005 DBMET00621 | DBMET00621 | |
| 0.025 | 0.061 | 0.052 | Endothelin-converting enzyme inhibitor | 0.052 0.029 DBMET00621 | DBMET00621 | |
| 0.028 | 0.064 | 0.075 | Glutamate (mGluR8) agonist | 0.075 0.004 DBMET00621 0.037 0.029 DBMET00634 | DBMET00621 | |
| 0.076 | 0.113 | 0.197 | Cystathionine beta-synthase inhibitor | 0.197 0.025 DBMET00621 0.101 0.076 DBMET00634 | DBMET00621 | |
| 0.016 | 0.053 | 0.026 | ICAM 1 antagonist | 0.024 0.013 DBMET00621 0.026 0.01 DBMET00634 | DBMET00634 | |
| 0.127 | 0.163 | 0.215 | Succinate dehydrogenase inhibitor | 0.215 0.038 DBMET00621 0.161 0.094 DBMET00634 | DBMET00621 | |
| 0.009 | 0.046 | 0.063 | VLA-4 antagonist | 0.063 0.01 DBMET00621 0.026 0.018 DBMET00634 | DBMET00621 | |
| 0.037 | 0.074 | 0.049 | HCV NS3/NS4A protease inhibitor | 0.049 0.035 DBMET00621 0.048 0.036 DBMET00634 | DBMET00621 | |
| 0.063 | 0.1 | 0.073 | Sphingosine 1-phosphate receptor antagonist | 0.073 0.064 DBMET00621 | DBMET00621 | |
| 0.012 | 0.049 | 0.022 | Imidazoline I1 receptor antagonist | 0.022 0.013 DBMET00621 | DBMET00621 | |
| 0.153 | 0.191 | 0.233 | RNA-directed DNA polymerase inhibitor | 0.233 0.062 DBMET00621 0.186 0.121 DBMET00634 | DBMET00621 | |
| 0.012 | 0.05 | 0.037 | Methionyl aminopeptidase 2 inhibitor | 0.037 0.01 DBMET00621 | DBMET00621 | |
| 0.032 | 0.071 | 0.101 | Glutamate (mGluR4) antagonist | 0.101 0.005 DBMET00621 0.041 0.036 DBMET00634 | DBMET00621 | |
| 0.047 | 0.086 | 0.305 | Histidine decarboxylase inhibitor | 0.305 0.006 DBMET00621 0.091 0.036 DBMET00634 | DBMET00621 | |
| 0.021 | 0.06 | 0.068 | NMDA receptor subunit 3A antagonist | 0.068 0.015 DBMET00621 0.045 0.022 DBMET00634 | DBMET00621 | |
| 0.02 | 0.059 | 0.062 | Protease activated receptor 1 antagonist | 0.062 0.026 DBMET00621 | DBMET00621 | |
| 0.088 | 0.128 | 0.132 | Cytokine production inhibitor | 0.132 0.078 DBMET00621 | DBMET00621 | |
| 0.031 | 0.07 | 0.036 | Integrin alpha1beta1 antagonist | 0.036 0.033 DBMET00621 | DBMET00621 | |
| 0.029 | 0.069 | 0.055 | Neurotensin receptor antagonist | 0.055 0.025 DBMET00621 0.046 0.031 DBMET00634 | DBMET00621 | |
| 0.036 | 0.076 | 0.043 | Heme oxygenase inhibitor | 0.043 0.03 DBMET00621 | DBMET00621 | |
| 0.048 | 0.088 | 0.161 | Porphobilinogen synthase inhibitor | 0.161 0.018 DBMET00621 | DBMET00621 | |
| 0.013 | 0.053 | 0.026 | Somatostatin 4 antagonist | 0.026 0.014 DBMET00621 | DBMET00621 | |
| 0.083 | 0.124 | 0.112 | Caspase 3 inhibitor | 0.112 0.072 DBMET00621 0.103 0.087 DBMET00634 | DBMET00621 | |
| 0.015 | 0.056 | 0.036 | Plasma kallikrein inhibitor | 0.036 0.021 DBMET00621 | DBMET00621 | |
| 0.069 | 0.111 | 0.091 | Gastric antisecretory | 0.091 0.077 DBMET00634 | DBMET00634 | |
| 0.021 | 0.063 | 0.052 | AMPA receptor agonist | 0.052 0.008 DBMET00621 | DBMET00621 | |
| 0.019 | 0.061 | 0.042 | Growth hormone secretagogue receptor antagonist | 0.042 0.021 DBMET00621 | DBMET00621 | |
| 0.019 | 0.061 | 0.033 | Phosphoglycerate kinase inhibitor | 0.033 0.027 DBMET00621 | DBMET00621 | |
| 0.038 | 0.08 | 0.113 | Biliverdin reductase inhibitor | 0.113 0.015 DBMET00621 | DBMET00621 | |
| 0.028 | 0.071 | 0.065 | Plasmin inhibitor | 0.065 0.026 DBMET00621 | DBMET00621 | |
| 0.01 | 0.053 | 0.018 | Complement factor D inhibitor | 0.018 0.014 DBMET00621 | DBMET00621 | |
| 0.05 | 0.093 | 0.092 | Thrombin inhibitor | 0.092 0.031 DBMET00621 0.083 0.038 DBMET00634 | DBMET00621 | |
| 0.016 | 0.059 | 0.027 | Nicotinic acid receptor 2 antagonist | 0.027 0.018 DBMET00621 | DBMET00621 | |
| 0.009 | 0.052 | 0.04 | AMPA 1 receptor antagonist | 0.04 0.015 DBMET00621 | DBMET00621 | |
| 0.016 | 0.06 | 0.027 | Calcium-sensing receptor agonist | 0.027 0.018 DBMET00621 | DBMET00621 | |
| 0.029 | 0.073 | 0.05 | Kallikrein inhibitor | 0.05 0.03 DBMET00621 | DBMET00621 | |
| 0.019 | 0.064 | 0.029 | Complement factor 1s inhibitor | 0.029 0.009 DBMET00621 | DBMET00621 | |
| 0.028 | 0.074 | 0.122 | Neuropeptide agonist | 0.122 0.022 DBMET00621 | DBMET00621 | |
| 0.006 | 0.052 | 0.025 | Melanocortin 3 antagonist | 0.025 0.022 DBMET00621 | DBMET00621 | |
| 0.033 | 0.08 | 0.089 | Glutamate (mGluR1) antagonist | 0.089 0.02 DBMET00621 | DBMET00621 | |
| 0.077 | 0.125 | 0.122 | Alkylator | 0.122 0.066 DBMET00621 0.101 0.087 DBMET00634 | DBMET00621 | |
| 0.176 | 0.223 | 0.231 | Sodium/bile acid cotransporter inhibitor | 0.231 0.149 DBMET00634 | DBMET00634 | |
| 0.027 | 0.076 | 0.06 | Carbonic anhydrase VB inhibitor | 0.06 0.035 DBMET00621 | DBMET00621 | |
| 0.039 | 0.089 | 0.133 | Phosphofructokinase-1 inhibitor | 0.133 0.022 DBMET00621 0.061 0.056 DBMET00634 | DBMET00621 | |
| 0.054 | 0.103 | 0.14 | Ornithine decarboxylase inhibitor | 0.14 0.014 DBMET00621 0.116 0.029 DBMET00634 | DBMET00621 | |
| 0.032 | 0.082 | 0.051 | Potassium channel (Inward rectifier) blocker | 0.051 0.033 DBMET00634 | DBMET00634 | |
| 0.013 | 0.063 | 0.036 | Lysine carboxypeptidase inhibitor | 0.036 0.012 DBMET00621 | DBMET00621 | |
| 0.058 | 0.11 | 0.084 | Cell adhesion molecule inhibitor | 0.084 0.048 DBMET00621 0.071 0.068 DBMET00634 | DBMET00621 | |
| 0.071 | 0.123 | 0.103 | Bile acid receptor antagonist | 0.103 0.042 DBMET00621 0.089 0.076 DBMET00634 | DBMET00621 | |
| 0.015 | 0.067 | 0.081 | Kainate receptor 2 antagonist | 0.081 0.006 DBMET00621 0.035 0.026 DBMET00634 | DBMET00621 | |
| 0.005 | 0.058 | 0.037 | Kainate receptor 1 antagonist | 0.037 0.008 DBMET00621 | DBMET00621 | |
| 0.161 | 0.213 | 0.366 | Transcription factor NF kappa B inhibitor | 0.366 0.072 DBMET00621 0.255 0.124 DBMET00634 | DBMET00621 | |
| 0.068 | 0.122 | 0.091 | Hematopoietic | 0.091 0.047 DBMET00621 | DBMET00621 | |
| 0.062 | 0.116 | 0.144 | HIV-1 integrase (Overall Integration) inhibitor | 0.144 0.028 DBMET00621 | DBMET00621 | |
| 0.024 | 0.078 | 0.061 | Adenosine deaminase inhibitor | 0.061 0.02 DBMET00621 | DBMET00621 | |
| 0.008 | 0.063 | 0.023 | Growth hormone releasing factor antagonist | 0.023 0.017 DBMET00621 | DBMET00621 | |
| 0.047 | 0.103 | 0.073 | Rho-associated kinase I inhibitor | 0.073 0.054 DBMET00621 | DBMET00621 | |
| 0.02 | 0.076 | 0.051 | Somatostatin 5 agonist | 0.051 0.012 DBMET00621 | DBMET00621 | |
| 0.009 | 0.065 | 0.059 | Somatostatin 2 antagonist | 0.059 0.012 DBMET00621 | DBMET00621 | |
| 0.031 | 0.087 | 0.088 | Glutamate (mGluR group III) antagonist | 0.088 0.006 DBMET00621 | DBMET00621 | |
| 0.053 | 0.11 | 0.121 | Glycine receptor agonist | 0.121 0.012 DBMET00621 | DBMET00621 | |
| 0.055 | 0.113 | 0.093 | Carbonic anhydrase VI inhibitor | 0.093 0.044 DBMET00621 | DBMET00621 | |
| 0.033 | 0.093 | 0.077 | Aconitate hydratase inhibitor | 0.077 0.015 DBMET00621 | DBMET00621 | |
| 0.004 | 0.064 | 0.018 | Glutamate (mGluR6) agonist | 0.018 0.005 DBMET00621 | DBMET00621 | |
| 0.031 | 0.093 | 0.046 | Glucose-6-phosphate isomerase inhibitor | 0.046 0.037 DBMET00621 | DBMET00621 | |
| 0.007 | 0.069 | 0.029 | Nicotinic acid receptor 1 antagonist | 0.029 0.004 DBMET00621 0.02 0.008 DBMET00634 | DBMET00621 | |
| 0.035 | 0.097 | 0.593 | 5 Hydroxytryptamine agonist | 0.593 0.004 DBMET00621 0.064 0.051 DBMET00634 | DBMET00621 | |
| 0.017 | 0.081 | 0.038 | Factor VIIa inhibitor | 0.038 0.027 DBMET00621 | DBMET00621 | |
| 0.044 | 0.109 | 0.114 | Caspase 9 inhibitor | 0.058 0.052 DBMET00621 0.114 0.01 DBMET00634 | DBMET00634 | |
| 0.01 | 0.074 | 0.074 | Glutamate (mGluR1a) agonist | 0.074 0.004 DBMET00621 | DBMET00621 | |
| 0.088 | 0.157 | 0.113 | Antibacterial (Helicobacter pylori) | 0.113 0.093 DBMET00621 | DBMET00621 | |
| 0.034 | 0.104 | 0.08 | NMDA 2 receptor antagonist | 0.08 0.044 DBMET00621 | DBMET00621 | |
| 0.015 | 0.085 | 0.037 | Integrin antagonist | 0.037 0.032 DBMET00621 | DBMET00621 | |
| 0.021 | 0.091 | 0.067 | Glutamate (mGluR group I) agonist | 0.067 0.018 DBMET00621 | DBMET00621 | |
| 0.058 | 0.129 | 0.122 | Alcohol dehydrogenase inhibitor | 0.122 0.033 DBMET00621 | DBMET00621 | |
| 0.01 | 0.083 | 0.023 | Bombesin agonist | 0.023 0.015 DBMET00621 | DBMET00621 | |
| 0.009 | 0.082 | 0.017 | Bombesin 3 receptor agonist | 0.017 0.016 DBMET00621 | DBMET00621 | |
| 0.065 | 0.139 | 0.104 | Protein kinase C zeta inhibitor | 0.104 0.046 DBMET00621 | DBMET00621 | |
| 0.039 | 0.113 | 0.057 | 5 Hydroxytryptamine 3 agonist | 0.057 0.055 DBMET00621 | DBMET00621 | |
| 0.099 | 0.174 | 0.186 | Hemostatic | 0.186 0.039 DBMET00621 | DBMET00621 | |
| 0.017 | 0.093 | 0.034 | Nicotinic receptor beta4 subunit antagonist | 0.034 0.03 DBMET00621 | DBMET00621 | |
| 0.066 | 0.142 | 0.103 | Electrolyte absorption antagonist | 0.103 0.053 DBMET00621 | DBMET00621 | |
| 0.024 | 0.103 | 0.083 | Plasminogen activator inhibitor | 0.083 0.024 DBMET00621 0.061 0.039 DBMET00634 | DBMET00621 | |
| 0.017 | 0.097 | 0.036 | Growth factor receptor-bound protein 2 antagonist | 0.036 0.023 DBMET00621 | DBMET00621 | |
| 0.089 | 0.169 | 0.162 | Phospholipase A2 inhibitor | 0.162 0.064 DBMET00621 | DBMET00621 | |
| 0.039 | 0.12 | 0.058 | Potassium channel intermediate-conductance Ca-activated blocker | 0.058 0.046 DBMET00621 | DBMET00621 | |
| 0.027 | 0.109 | 0.127 | Alcohol oxidase inhibitor | 0.127 0.013 DBMET00621 | DBMET00621 | |
| 0.019 | 0.103 | 0.044 | AMPA receptor antagonist | 0.044 0.038 DBMET00621 | DBMET00621 | |
| 0.013 | 0.098 | 0.03 | Thyroid hormone agonist | 0.03 0.013 DBMET00621 | DBMET00621 | |
| 0.03 | 0.116 | 0.057 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.057 0.038 DBMET00621 | DBMET00621 | |
| 0.01 | 0.096 | 0.058 | Sirtuin 2 inhibitor | 0.058 0.01 DBMET00621 0.035 0.021 DBMET00634 | DBMET00621 | |
| 0.112 | 0.198 | 0.162 | Focal adhesion kinase 2 inhibitor | 0.155 0.123 DBMET00621 0.162 0.111 DBMET00634 | DBMET00634 | |
| 0.008 | 0.095 | 0.018 | Somatostatin 3 antagonist | 0.018 0.016 DBMET00621 | DBMET00621 | |
| 0.052 | 0.141 | 0.066 | MDM2 inhibitor | 0.066 0.051 DBMET00621 | DBMET00621 | |
| 0.061 | 0.149 | 0.09 | Polo-like kinase-1 inhibitor | 0.09 0.061 DBMET00621 | DBMET00621 | |
| 0.086 | 0.175 | 0.323 | Angiogenesis stimulant | 0.323 0.041 DBMET00621 0.16 0.116 DBMET00634 | DBMET00621 | |
| 0.012 | 0.101 | 0.314 | 5 Hydroxytryptamine 2C agonist | 0.314 0.004 DBMET00621 | DBMET00621 | |
| 0.009 | 0.099 | 0.037 | AMPA 2 receptor antagonist | 0.037 0.016 DBMET00621 | DBMET00621 | |
| 0.103 | 0.197 | 0.156 | CF transmembrane conductance regulator agonist | 0.156 0.066 DBMET00621 0.131 0.115 DBMET00634 | DBMET00621 | |
| 0.045 | 0.14 | 0.132 | NMDA receptor antagonist | 0.132 0.03 DBMET00621 0.074 0.073 DBMET00634 | DBMET00621 | |
| 0.046 | 0.141 | 0.08 | Exportin-1 inhibitor | 0.08 0.026 DBMET00621 | DBMET00621 | |
| 0.022 | 0.118 | 0.046 | Glutamate (mGluR5) agonist | 0.046 0.032 DBMET00621 | DBMET00621 | |
| 0.049 | 0.147 | 0.107 | Urease inhibitor | 0.107 0.059 DBMET00621 0.091 0.078 DBMET00634 | DBMET00621 | |
| 0.08 | 0.178 | 0.132 | Protein kinase stimulant | 0.132 0.082 DBMET00621 | DBMET00621 | |
| 0.101 | 0.202 | 0.123 | Pregnane X receptor agonist | 0.123 0.122 DBMET00621 | DBMET00621 | |
| 0.146 | 0.247 | 0.2 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.2 0.157 DBMET00621 | DBMET00621 | |
| 0.022 | 0.124 | 0.047 | Neuraminidase (Influenza A) inhibitor | 0.047 0.029 DBMET00621 | DBMET00621 | |
| 0.062 | 0.164 | 0.085 | MAP kinase kinase 1 inhibitor | 0.085 0.079 DBMET00621 | DBMET00621 | |
| 0.045 | 0.148 | 0.135 | Antiadrenergic | 0.135 0.04 DBMET00634 | DBMET00634 | |
| 0.083 | 0.187 | 0.115 | Sphingosine 1-phosphate receptor 2 agonist | 0.115 0.063 DBMET00621 | DBMET00621 | |
| 0.054 | 0.16 | 0.11 | Factor XII inhibitor | 0.11 0.03 DBMET00621 | DBMET00621 | |
| 0.057 | 0.163 | 0.14 | 5 Hydroxytryptamine 3A agonist | 0.14 0.041 DBMET00621 | DBMET00621 | |
| 0.042 | 0.149 | 0.127 | Adrenaline antagonist | 0.127 0.041 DBMET00634 | DBMET00634 | |
| 0.027 | 0.138 | 0.05 | Potassium channel (ATP-sensitive) activator | 0.047 0.036 DBMET00621 0.05 0.03 DBMET00634 | DBMET00634 | |
| 0.029 | 0.141 | 0.052 | Potassium channel (Inward rectifier) activator | 0.049 0.038 DBMET00621 0.052 0.031 DBMET00634 | DBMET00634 | |
| 0.068 | 0.18 | 0.217 | Thrombolytic | 0.217 0.044 DBMET00621 | DBMET00621 | |
| 0.087 | 0.2 | 0.155 | LIM domain kinase 1 inhibitor | 0.155 0.093 DBMET00621 | DBMET00621 | |
| 0.102 | 0.218 | 0.171 | Platelet antagonist | 0.171 0.125 DBMET00621 | DBMET00621 | |
| 0.115 | 0.237 | 0.204 | DNA damaging | 0.204 0.112 DBMET00621 | DBMET00621 | |
| 0.082 | 0.207 | 0.124 | Mannose-6-phosphate isomerase inhibitor | 0.124 0.095 DBMET00621 | DBMET00621 | |
| 0.044 | 0.17 | 0.111 | Keratolytic | 0.111 0.025 DBMET00621 | DBMET00621 | |
| 0.033 | 0.159 | 0.059 | I kappa B kinase 2 inhibitor | 0.059 0.049 DBMET00621 | DBMET00621 | |
| 0.066 | 0.193 | 0.096 | Nav1.5 sodium channel blocker | 0.096 0.092 DBMET00634 | DBMET00634 | |
| 0.082 | 0.21 | 0.117 | Aurora-C kinase inhibitor | 0.117 0.114 DBMET00634 | DBMET00634 | |
| 0.014 | 0.142 | 0.037 | Carbonic anhydrase I stimulant | 0.037 0.027 DBMET00621 | DBMET00621 | |
| 0.038 | 0.166 | 0.072 | Acetylcholine nicotinic agonist | 0.072 0.068 DBMET00634 | DBMET00634 | |
| 0.089 | 0.221 | 0.185 | DNA methylase inhibitor | 0.185 0.089 DBMET00621 | DBMET00621 | |
| 0.057 | 0.191 | 0.102 | Beta amyloid protein antagonist | 0.102 0.087 DBMET00621 | DBMET00621 | |
| 0.037 | 0.177 | 0.121 | Protein kinase B gamma inhibitor | 0.121 0.025 DBMET00621 | DBMET00621 | |
| 0.075 | 0.216 | 0.149 | Cell wall synthesis inhibitor | 0.149 0.067 DBMET00621 0.143 0.072 DBMET00634 | DBMET00621 | |
| 0.012 | 0.153 | 0.072 | Urokinase inhibitor | 0.072 0.024 DBMET00621 | DBMET00621 | |
| 0.018 | 0.163 | 0.042 | Dihydroorotase inhibitor | 0.042 0.035 DBMET00621 | DBMET00621 | |
| 0.042 | 0.187 | 0.093 | Potassium channel activator | 0.093 0.056 DBMET00634 | DBMET00634 | |
| 0.023 | 0.17 | 0.045 | GABA B receptor antagonist | 0.045 0.027 DBMET00621 | DBMET00621 | |
| 0.083 | 0.23 | 0.268 | Interleukin antagonist | 0.268 0.055 DBMET00621 0.145 0.122 DBMET00634 | DBMET00621 | |
| 0.005 | 0.158 | 0.041 | Somatostatin 5 antagonist | 0.041 0.018 DBMET00621 | DBMET00621 | |
| 0.028 | 0.181 | 0.054 | Carbonic anhydrase II stimulant | 0.054 0.032 DBMET00621 | DBMET00621 | |
| 0.143 | 0.296 | 0.373 | Caspase 3 stimulant | 0.373 0.052 DBMET00634 | DBMET00634 | |
| 0.025 | 0.182 | 0.108 | Glutamate receptor agonist | 0.108 0.032 DBMET00621 | DBMET00621 | |
| 0.008 | 0.169 | 0.03 | Histamine H3 receptor agonist | 0.03 0.018 DBMET00621 | DBMET00621 | |
| 0.125 | 0.294 | 0.323 | Immunosuppressant | 0.323 0.101 DBMET00621 0.238 0.158 DBMET00634 | DBMET00621 | |
| 0.031 | 0.2 | 0.12 | Protein kinase B alpha inhibitor | 0.12 0.018 DBMET00621 | DBMET00621 | |
| 0.053 | 0.223 | 0.085 | D-Ala-D-Ala ligase inhibitor | 0.085 0.055 DBMET00621 | DBMET00621 | |
| 0.018 | 0.189 | 0.057 | Phenylethanolamine N methyltransferase inhibitor | 0.057 0.009 DBMET00621 | DBMET00621 | |
| 0.01 | 0.184 | 0.035 | Glutamate (mGluR group II) antagonist | 0.035 0.031 DBMET00621 | DBMET00621 | |
| 0.028 | 0.202 | 0.1 | Sirtuin 1 inhibitor | 0.1 0.022 DBMET00621 | DBMET00621 | |
| 0.019 | 0.194 | 0.063 | Glutamate (mGluR group III) agonist | 0.063 0.017 DBMET00621 | DBMET00621 | |
| 0.063 | 0.24 | 0.175 | Anticoagulant | 0.175 0.063 DBMET00621 | DBMET00621 | |
| 0.073 | 0.255 | 0.15 | DNA methyltransferase I inhibitor | 0.15 0.104 DBMET00621 | DBMET00621 | |
| 0.05 | 0.232 | 0.154 | Transcription factor NF kappa B stimulant | 0.085 0.059 DBMET00621 0.154 0.015 DBMET00634 | DBMET00634 | |
| 0.028 | 0.214 | 0.136 | Monophenol monooxygenase inhibitor | 0.136 0.053 DBMET00621 | DBMET00621 | |
| 0.08 | 0.271 | 0.139 | Tumour necrosis factor antagonist | 0.139 0.115 DBMET00621 0.131 0.125 DBMET00634 | DBMET00621 | |
| 0.028 | 0.225 | 0.053 | Alpha 1b adrenoreceptor agonist | 0.053 0.03 DBMET00634 | DBMET00634 | |
| 0.045 | 0.243 | 0.158 | Histone deacetylase class III inhibitor | 0.158 0.038 DBMET00621 | DBMET00621 | |
| 0.015 | 0.215 | 0.04 | Glutamate (mGluR4) agonist | 0.04 0.016 DBMET00621 | DBMET00621 | |
| 0.038 | 0.249 | 0.135 | Aminoacyl-tRNA synthetase inhibitor | 0.135 0.024 DBMET00621 0.134 0.024 DBMET00634 | DBMET00621 | |
| 0.013 | 0.23 | 0.039 | Acetyl-CoA carboxylase inhibitor | 0.039 0.032 DBMET00634 | DBMET00634 | |
| 0.018 | 0.238 | 0.052 | Glutamate (mGluR8) antagonist | 0.052 0.008 DBMET00621 | DBMET00621 | |
| 0.035 | 0.255 | 0.277 | Bronchodilator | 0.107 0.056 DBMET00621 0.277 0.01 DBMET00634 | DBMET00634 | |
| 0.056 | 0.284 | 0.204 | Histone deacetylase SIRT1 inhibitor | 0.204 0.029 DBMET00621 0.132 0.078 DBMET00634 | DBMET00621 | |
| 0.122 | 0.351 | 0.246 | Antibacterial | 0.222 0.205 DBMET00621 0.246 0.181 DBMET00634 | DBMET00634 | |
| 0.041 | 0.279 | 0.144 | Amylase inhibitor | 0.144 0.067 DBMET00621 | DBMET00621 | |
| 0.069 | 0.319 | 0.196 | Non-steroidal antiinflammatory agent | 0.196 0.075 DBMET00621 | DBMET00621 | |
| 0.017 | 0.272 | 0.073 | Histone deacetylase SIRT2 inhibitor | 0.073 0.051 DBMET00621 | DBMET00621 | |
| 0.017 | 0.33 | 0.078 | Protein kinase A inhibitor | 0.078 0.062 DBMET00621 | DBMET00621 | |
| 0.036 | 0.354 | 0.144 | Pyruvate kinase inhibitor | 0.144 0.121 DBMET00621 | DBMET00621 | |
| 0.005 | 0.344 | 0.095 | Beta tubulin antagonist | 0.095 0.024 DBMET00634 | DBMET00634 | |
| 0.028 | 0.367 | 0.207 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.207 0.048 DBMET00621 | DBMET00621 | |
| 0.038 | 0.378 | 0.123 | Protein kinase (CK1) gamma 3 inhibitor | 0.123 0.122 DBMET00621 | DBMET00621 | |
| 0.047 | 0.424 | 0.142 | Interleukin 6 antagonist | 0.142 0.101 DBMET00621 0.137 0.11 DBMET00634 | DBMET00621 | |
| 0.039 | 0.432 | 0.093 | Toll-Like receptor 3 antagonist | 0.093 0.062 DBMET00634 | DBMET00634 | |
| 0.024 | 0.429 | 0.123 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.123 0.113 DBMET00621 | DBMET00621 | |
| 0.089 | 0.506 | 0.69 | Apoptosis agonist | 0.69 0.032 DBMET00634 | DBMET00634 | |
| 0.049 | 0.55 | 0.212 | Hypoglycemic | 0.212 0.101 DBMET00621 | DBMET00621 | |
| 0.098 | 0.61 | 0.195 | MAP kinase kinase 3 inhibitor | 0.195 0.137 DBMET00621 | DBMET00621 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |